第一金融网主办
»您现在的位置: 第一金融网 >> 金融焦点 >> 文传商讯 >> 正文

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

2018/6/27 8:30:57  文章来源:文传商讯  作者:文传商讯
文章简介: INGELHEIM,GermanyandINDIANAPOLIS--(BUSINESSWIRE)--BoehringerIngelheimandEliLillyandCompany(NYSE:LLY)todayannouncedthatbothrandomisedcon

INGELHEIM, Germany and INDIANAPOLIS--(BUSINESS WIRE)--Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. The primary efficacy endpoint, defined in both trials as placebo-corrected change from baseline in HbA1c after 26 weeks of treatment, was met for all investigated doses of empagliflozin (2.5, 10, and 25 mg).

Type 1 diabetes currently affects approximately 30 million adults worldwide.1 It is an autoimmune disease in which the body does not produce sufficient amounts of insulin and therefore requires life-long daily insulin administration to regulate blood sugar. For some people with type 1 diabetes, it may be challenging to manage blood sugar levels with insulin alone. People with type 1 diabetes also face risks of complications such as sight loss, heart disease, kidney disease and amputations.

“Despite recent advances in insulin therapy and patient care, optimal glucose control is difficult to achieve in people with type 1 diabetes. Empagliflozin is an effective and well-established medicine used to treat adults with type 2 diabetes, and our comprehensive clinical trial programme continues to investigate the potential benefits it may offer to a range of adults with diabetes”, said Dr. Jyothis George, Global Head of Clinical Development, Therapeutic Area CardioMetabolism, Boehringer Ingelheim. “Boehringer Ingelheim and Lilly look forward to sharing the results of the EASE phase III programme at EASD.”

The safety profile in both studies was generally consistent with the previously reported safety profile of empagliflozin. The number of adjudicated diabetic ketoacidosis events was comparable between empagliflozin 2.5 mg and placebo and higher than placebo in adults with type 1 diabetes on empagliflozin 10 mg and 25 mg.

The full results from the EASE phase III programme will be presented at the European Association for the Study of Diabetes Annual Meeting on 4th October, 2018 in Berlin, Germany.

Empagliflozin is currently not approved for use in people with type 1 diabetes. Boehringer Ingelheim and Lilly are discussing next steps and exploring regulatory options.

About Diabetes

An estimated 425 million adults worldwide have type 1 and type 2 diabetes.2 Type 2 diabetes is the most common form, accounting for around 90 percent of all cases.2 Diabetes is a chronic disease that occurs when the body does not properly produce, or use, the hormone insulin.

About the EASE phase III programme

The EASE phase III programme includes two multinational, double-blinded, placebo-controlled Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin as Adjunctive to inSulin thErapy in adults with type 1 diabetes (EASE), an indication for which empagliflozin is currently not approved.

  • EASE-2 [NCT02414958] evaluated 10 mg and 25 mg doses of empagliflozin as adjunct to insulin versus placebo for 52 weeks.3
    Primary endpoint: Change from baseline in HbA1c after 26 weeks of treatment
    Number of patients: 720
  • EASE-3 [NCT02580591] compared 10 mg and 25 mg doses of empagliflozin as adjunct to insulin versus placebo for 26 weeks. Additionally, a lower dose of empagliflozin (2.5 mg) was investigated in this trial4
    Number of patients: 960

About SGLT2 inhibitors and empagliflozin

Empagliflozin is an SGLT2 inhibitor which provides blood sugar control with additional benefits of weight loss and lowering blood pressure* in adults with type 2 diabetes. Empagliflozin is the first and only oral diabetes medicine approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. The benefit-risk profile of empagliflozin has been well-established in its approved indications.

Type 1 diabetes is currently not an approved indication of empagliflozin.

* Jardiance® is not indicated for weight loss or blood pressure reduction.

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/type-1-diabetes

 

分享到:
  • 上一篇文章:

  • 下一篇文章: 没有了
  • 第一金融网免责声明:
    1、本网站中的文章(包括转贴文章)的版权仅归原作者所有,若作者有版权声明的或文章从其它网站转载而附带有原所有站的版权声明者,其版权归属以附带声明为准。
    2、文章来源为均为其它媒体的转载文章,我们会尽可能注明出处,但不排除来源不明的情况。转载是处于提供更多信息以参考使用或学习、交流、科研之目的,不用于 商业用途。转载无意侵犯版权,如转载文章涉及您的权益等问题,请作者速来电话和函告知,我们将尽快处理。来信:fengyueyoubian#sina.com (请将#改为@)。
    3、本网站所载文章、数据、网友投稿等内容纯属作者个人观点,仅供投资者参考,并不构成投资建议,与第一金融网站无关。投资者据此操作,风险自担。如对本文内容有疑义,请及时与我们联系。
    发表评论

    【发表评论】(网友评论内容只代表网友观点,与本站立场无关!)
     姓 名:
     评 分: 1分 2分 3分 4分 5分
     评论内容:
    验证码:   *
  • 请遵守《互联网电子公告服务管理规定》及中华人民共和国其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏社会稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • 全站精选
    [新闻]  人民币中间价下调287点 连跌五天调降近千点
     输球要被判死刑?韩请愿网站成施加网络暴力场所
    [银行]  中行行长人选出炉!由原进出口银行行长刘连舸出
     赃款未追缴 龙江银行原副行长减刑建议被驳回
    [股票]  明日股市三大猜想及应对策略:创蓝筹迎来机会
     许家印买下FF成贾跃亭的老板 入股45%成第一大股
    [基金]  “老鼠仓”监管升级!跟着私募基金炒股,被罚10
     创业板ETF持续扩大 盯创业板漂亮100(附股)
    [保险]  保险巨头中国太平洋人寿保险宣布16亿元投资蚂蚁
     欺骗投保人!幸福人寿宣称:保险公司不能破产及
    [期货]  一天不止赚一倍 “苹果”火爆背后有人疯狂做文章
     原油期货上市带火原油场外期权
    [股评]  机构预测明日大盘走势(6/27)
     A股已是遍地黄金 紧盯7只市盈率低于10倍股
    [港股]  腾讯今日头条同时报案追剿“黑公关”  称遭遇有
     美团赴港IPO 传筹468亿港元
    [美股]  陌陌持续13个季度盈利 2018年Q1净利9亿人民币
     抄袭的代价!58同城因它被判需赔601万元!
    [外汇]  美元指数反弹站上90大关:美联储货币收紧的节奏
     三月外汇储备正增长:外汇市场延续供求平衡格局
    [债券]  中国信用债发行成本创2014年来新高
     人行摸底排查企业债违约风险
    [黄金]  互金协会禁令:禁止以“创始会员”名义宣传
     黄金热下的黑平台骗局:宣称百分百盈利 诱使客户
    [理财]  出了国才明白,为什么我和孩子都曾经那么累
     “我哭了整整一年” 中国留学生如何走出心理低谷
    [信托]  银保监会:强化监管力度,进一步整治信托业市场
     影子银行迎来强检查 部分信托公司暂停通道业务
    [房产]  杭州:暂停向企事业单位及其他机构销售住房
     长沙楼市调控全面升级:二手房四至五年限售
    [汽车]  “十次事故九次快”!超速行驶有哪些危害你知道吗
     7月1日起我国对购置挂车将减半征收车辆购置税
  • 此栏目下没有推荐文章
  • | 设为首页 | 加入收藏 | 关于我们 | 友情链接 | 版权申明 | 文章列表 | 网站地图 | 征稿启事 | 广告服务 | 意见反馈 |

    Copyright©2006-2017 afinance.cn All Rights Reserved 版权所有·第一金融网 ,未经授权禁止复制或建立镜像,否则将依法追究法律责任!

    声明:我们不做任何形式的代客理财及投资指导,凡是以第一金融网名义做股票推荐的行为均属违法!

    广告商的言论与行为均与第一金融网无关!股市有风险,投资需谨慎。

    合作邮箱:fengyueyoubian@sina.com 合作电话:18678839953 点击这里给我发消息